Join Steven Horwitz, MD and Laura Tang, PharmD, BCOP from Memorial Sloan Kettering Cancer Center as they present their expertise on a range of cases pertaining to peripheral T-cell lymphomas.
Peripheral T‑cell lymphomas (PTCL) are a heterogeneous group of aggressive non-Hodgkin’s lymphomas (NHL), accounting for about 10% of NHL. The most common subtypes include PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and anaplastic large cell lymphoma (ALCL). Enteropathy-associated T-cell lymphoma (EATL) is a rare subtype occurring in less than 5% of patients. Anthracycline-based multiagent chemotherapy is the standard first-line therapy. However, with the exception of ALK-positive ALCL, other subtypes (PTCL-NOS, AITL and EATL) are associated with lower response rates to first-line chemotherapy alone and responses are not durable. Patients with these subtypes often receive high-dose therapy and autologous stem cell rescue (HDT/ASCR) following first-line therapy. Relapsed or refractory disease is managed with second-line chemotherapy followed by HDT/ASCR or allogeneic stem cell transplant, based on the patient’s eligibility for transplant but treatment for this group of patients remains suboptimal.
NCCN is offering a series of twelve multidisciplinary case-based webinars on a variety of topics, bladder cancer, breast cancer, colorectal cancer, kidney cancer, lung cancer, melanoma, multiple myeloma, myelofibrosis, ovarian cancer, peripheral T-cell lymphomas, prostate cancer and sarcoma. Each webinar will be facilitated by at least two faculty members. A different topic will be presented each month for twelve months (June 2016 until June 2017). The goal of this Series is to ensure that members of a multidisciplinary team, including physicians, nurses, pharmacists and other relevant healthcare professionals, have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with various cancer types.
The NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®) are a set of step-by step evidence-based, consensus-driven recommendations that ensure that patients receive preventive, diagnostic treatment, and care that is most likely to lead to optimal outcomes. The NCCN recommendations are applicable to about 95% of patients. Clinicians need to consider the current clinical status of the patient, including general health, disease specifics, concomitant conditions, current and previous therapies, and the patients how to best apply appropriate standard of care including identifying circumstances where appropriate management requires adapting the NCCN Guidelines to the needs of the individual. This activity series will discuss the specific recommendations in the NCCN Guidelines as well as unique patient circumstances that impact how the NCCN Guidelines might be best applied.
Friday, April 7, 2017 3:30 PM - 4:30 PMEastern Time
NCCN Meetings Department
World Time Zone MapSee when meeting occurs in other time zonesWorld Time Zone Map
NCCN.org – For Clinicians | NCCN.org/patients – For Patients
National Comprehensive Cancer Network | 275 Commerce Drive | Suite 300 | Fort Washington | PA | 19034 | US | 215.690.0300